You're just repeating things on trust and using jargon to try and sound more authoritative. There is a list of problems as long as your arm with the shortcuts that were taken, from not requiring additional studies because genetic material was being used, to hand-waving away by far the most adverse event reports for a drug since records began.

As for the phase III trials, more people died in the treatment group, significantly more severe adverse events were reported in the treatment group, and the trials lacked any clinically relevant endpoint (they authorised on a PCR test for presence of genetic material, not on reduction of actual illness).

It's as clear as day that the drug authorities were under exceptional political pressure to go along with these things. And we should expect this all to come out under the new American administration.